dsm-firmenich outlines action plan at Investor Event to accelerate performance, following completion of transformation

Core Viewpoint - dsm-firmenich is focusing on accelerating performance following its transformation into a fully consumer-focused company, with a strategic plan to enhance financial performance and operational efficiency [2][3]. Company Overview - dsm-firmenich operates in nutrition, health, and beauty, with revenues exceeding €9 billion for its Continuing Operations after divesting Animal Nutrition & Health [9]. - The company has a global presence in nearly 60 countries and employs around 21,000 people [9]. Strategic Actions - The company has completed a portfolio upgrade and achieved €175 million in cost synergies from its merger integration, positioning itself for improved financial performance [2]. - A multi-lever plan is in place to drive growth, expand EBITDA margins, and enhance cash conversion, while maintaining disciplined capital allocation and normalizing capital expenditure [3]. Financial Outlook - For the full year 2026, dsm-firmenich anticipates cautious consumer demand and adverse foreign exchange effects to impact performance [5]. - The company aims to achieve mid-term targets for Organic Sales Growth and Adjusted EBITDA margin by 2028, with an increased target for Adjusted Gross Operating Free Cash Flow from ≥10% to ≥14% [6]. Share Repurchase Program - dsm-firmenich has announced a new share repurchase program totaling €540 million, with €500 million aimed at reducing issued capital and €40 million for share-based compensation commitments [7]. Performance Metrics - The company projects organic sales growth of 2–4%, an Adjusted EBITDA margin of around 20%, and a cash conversion rate of 11–12% for Adjusted Gross Operating Free Cash Flow to Sales [8].